Journals / Retina-Vitreus / 2001 / Cilt: 9 - Sayı: 3

Grid or focal argon laser photocoagulation for diabetic maculopathy: Results and predictors of visual outcomes

Diabetik makulopatide argon lazer fokal ve grid fotokoagülasyon sonrası görsel sonuçlarımız ve tedavinin başarısını etkileyen faktörler

Pages
232–239
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

But, we found statistically significant association between systemic problems, systemic vascular disease and bad visual outcomes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the results of argon lazer photocoagulation for diabetic maculopathy and to determine the predictors of visual outcome.
📊
Key Findings & Data:Methods: Fifty-eight eyes of 31 patients who underwent argon lazer photocoagualtion for diabetic maculopathy were evaluated retrospectively.
💡
Conclusion & Impact:But, we found statistically significant association between systemic problems, systemic vascular disease and bad visual outcomes.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Geriyedönük çalışma · Oftalmolojik cerrahi işlemler · Görme keskinliği

Abstract

Purpose: To evaluate the results of argon lazer photocoagulation for diabetic maculopathy and to determine the predictors of visual outcome. Methods: Fifty-eight eyes of 31 patients who underwent argon lazer photocoagualtion for diabetic maculopathy were evaluated retrospectively. Routine ophthalmic examination including fluorescein angiography and fundus photography were performed. Blood glucose level and presence of systemic vascular disease and/or hypertension were evaluated from patients' records. Thirty eyes with focal maculopathy were treated with argon green focal photocoagulation and 28 eyes with diffuse maculopathy were treated with argon green grid photocoagulation. Visual improvement, visual loss, and the association between visual outcomes and hypertension or systemic vascular disease were assessed. Results: Thirty seven (% 63.8) eyes had non-proliferative diabetic retinopathy and 21 (% 36.2) eyes had proliferative diabetic retinopathy. However, 12 (% 40) eyes had improved visual acuity, 18 (% 60) eyes had stable visual acuity and no eyes had worsened visual acuity in the focal lazer group. Whereas, 3 (% 10.7) eyes had better, 18 (% 64.3) eyes had stable and 7 (% 25) eyes had worse visual acuity after grid lazer photocoagulation in the diffuse maculopathy group. If hypertension and systemic vascular disease were associated with macular edema, there were a significant decline in the outcomes after lazer photocoagulation. Conclusions: The results of our study support previously published reports, suggesting the beneficial effects of grid or focal lazer photocoagulation in diffuse or focal macular edema. The treatment greatly maintain pretreatment visual acuity. But, we found statistically significant association between systemic problems, systemic vascular disease and bad visual outcomes.

Özet

Amaç: Diabetik makulopati nedeniyle argon lazer fotokoagülasyon uyguladığımız olgularımızı değerlendirmek, tedavinin başarısını ve son görmeyi etkileyen faktörleri incelemek. Gereç-Yöntem: Diabetik makulopati nedeniyle argon lazer fotokoagülasyon uyguladığımız 31 hastanın 58 gözü retrospektif olarak incelendi. Tüm olguların tedavi öncesi ve sonrası renkli fundus fotoğrafı ve fundus floresein anjiografisi çekildi. Bunun yanısıra tüm olgular Dahiliye kliniğine konsülte edildi ve açlık kan şekeri, hipertansiyon ve sistemik damar hastalığı incelendi. Fokal makulopati saptanan 30 göze fokal, diffüz makulopati saptanan 28 göze grid tarzı argon lazer uygulandı. Olguların tedavi öncesi ve sonrası görme keskinlikleri değerlendirildi. Bulgular: Otuz yedi gözde (%63.8) nonproliferatif diabetik retinopati, 21 gözde (%36.2) proliferatif diabetik retinopati saptandı. Fokal makula ödemi saptanarak fokal lazer uygulanan hasta grubunda; 12 (% 40) gözde görme keskinliğinde artma, 18 (% 60) gözde korunma belirlenirken, hiçbir gözde görme keskinliğinde azalma izlenmedi. Diffüz makula ödemi saptanarak grid lazer uygulanan hasta grubunda ise görme keskinliğinde 3 gözde (% 10.7) artma, 18 göz de (%64.3) korunma ve 7 gözde (%25) ise azalma saptandı. Açlık kan şekeri yüksek olan olgularda, hipertansiyon ve sistemik damar hastalığının eşlik ettiği olgularda tedaviye yanıtın istatistiksel olarak anlamlı düzeyde düştüğü belirlendi. Sonuç: Diabetik makulopatili olgularda lazer uygulaması sonrasında büyük oranlarda görme korunmaktadır. Sistemik sorunların eşlik ettiği olgularda tedaviye yanıt azalmaktadır.

🔖

Cite This Article

TANER, P., AKARSU, C., ERGİN, A., VURAL, E. (2001). Grid or focal argon laser photocoagulation for diabetic maculopathy: Results and predictors of visual outcomes. Retina-Vitreus, Cilt: 9 - Sayı: 3, 232–239. https://ajindex.com/articles/305422

References (16)

  1. Aiello LM, Cavalerano J, Aiello LP: Diagnosis, Management and Treatment of Nonproliferative Diabetic Rethinopathy and macular edema. In: Principles and Practice of Ophthalmology. 2'nd edition. V:3. eds: Albert DM, Jacobiec FA. Philadelphia PP: 1900-1914
  2. Early Tratment Diabetic Retinopathy Study Group. Treatment technigues and clinical guidelines for pho-tocoagulation of diabetic macular edema. ETDRS report 2. Ophthalmology 1987; 94:761- 774
  3. Klein R, Moss SE, Klein BE, Gutierrez P, Mangione CM. The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologie Study of Diabetic Retinopathy. Arch Ophthalmol 2001;119:733-40
  4. Leys AM. Eye fundus of the diabetic patient with nephropathy and hypertensive retinopathy. Mac-roangiopathic complications. Bull Soc Belge Ophtalmol 1995;256:49-59 (Abstract)
  5. Perkovich BT, Meyers SM. Systemic factors affecting diabetic macular edema. Am J Ophthalmol 1988; 105:211-2
  6. Early Tratment Diabetic Retinopathy Study Research Group: detection of diabetic macular edema: Oph-thalmoscopy vs. photography. ETDRS report No:5. Ophthalmology. 96:746, 1989
  7. Özkan Ş: Makula Ödeminin Tanısı Ret-Vit 8(1):7-17, 2000 8. Ünal M, Günalp İ, Tezel T: Diabetik makulopatide fokal ve grid argon lazer fotokoagülasyon. 1988; 18:471-5
  8. Çeliker Ü, Esmergil S, Çelebi S, Kükner Ş: Diabetik makulopatide fotokoagülasyon sonrası görsel sonuçlarımız. Ret-Vit 1995; 3: 384- 87
  9. Akkaya A, Yararcan M, Akın İ, Akyol F, Çakmaklı Z: Fokal Diabetik makulopatide argon lazer fokal fotokoagülasyon sonuçlarımız. Ret-Vit 1998; 6: 7-12
  10. Lee CM, Olk RJ: Modified grid lazer photocoagulation for diffuse diabetic macular edema. Ophthalmology 1991; 98:1594- 1602
  11. Esgin H, Uzun A, Erda S: Diabetik makuler ödemde fotokoagülasyon sonuçlarımız. Ret-Vit 1999;7:196-202
  12. Browning DJ, Antoszyk AN:The effect of the surgeon and the lazer wavelenght on the response to focal photocoagulation for diabetic macular edema. Ophthalmology 1999; 106:243-248
  13. Gelişken Ö, Yazıcı B: Makula Ödeminde Tedavi. Ret-Vit 2000; 8:27-33
  14. Olk RJ: Modified grid argon (blue-green) lazer photocoagulation for diffuse diabetic macular edema. Ophthalmology 1986; 93:938-950
  15. Olk RJ: Argon green (514 nm) versus krypton red (647 nm) modified grid lazer fo" diffuse diabetic macular edema. Long term visual results. Ophthalmol 1991; 98:1594-602
  16. Akduman L, Olk RJ: Diode Lazer (810 nm) versus argon green (514 nm) modified gfid photocoagula